The Tencent-backed cosmetic procedure-booking and social media platform floated at the top of its range in a US offering that came after more than $229m of funding.

Pharmstandard, Lung Biotechnology and Posco celebrated exits as the organ transportation system developer went public in a $91m offering.

Alexandria Real Estate Equities-backed exosome therapeutics developer Codiak BioSciences is eyeing up to $86.3m in a forthcoming IPO.

The immuno-oncology therapy developer received funding from investors including Alexandria Real Estate Equities and strategic collaborator Celgene.

The Eli Lilly and Mitsui-backed drug developer has received $11m in a round led by Cell Innovation Partners, taking its overall funding to more than $83m.

Taikang Life Insurance backed a $14.8m round for the online medical data platform, which already counts Fosun, DXY and Meituan Dianping as shareholders.

908 Devices plans to add a life science device to its chemical detection product range, having landed $17.5m in a Schlumberger and Saudi Aramco-backed round.

Telus Ventures is set to exit healthcare data management software producer Get Real Health in an $11m purchase by CPSI, six years after it invested.

MRCF has reached the first close of a CSL-backed fifth fund to make early-stage investments in medical technologies in Australia and New Zealand.

Digital China Health Technologies chipped into the third tranche of a round featuring fellow corporates BGI Genomics and Healthlink that now tops $30m.